Cardiology

Monitoring and Warning Signs

At a Glance

After a heart attack, call 911 for recurrent chest pain, severe trouble breathing, fainting, stroke signs, or major bleeding. Track weight, swelling, energy, and medication effects, and attend follow-up tests to see whether heart function is recovering and whether a defibrillator may be needed.

The weeks following a heart attack are a period of transition. While your heart is remarkably resilient, it is also in a vulnerable state of healing. Monitoring your body is not about living in fear; it is about knowing which signals are “normal” recovery and which require immediate action to protect your progress.

When to Call 911 Immediately

Some symptoms indicate a life-threatening complication, such as a second heart attack, a dangerous heart rhythm, or a major bleed. Do not drive yourself to the hospital if you experience:

Recurrent Chest Pain or Discomfort: Any pressure, squeezing, or pain in your chest, arms, neck, or jaw. This could feel like your original heart attack or present entirely differently as new unexplained discomfort or severe weakness ^[1]^[2].
Severe Shortness of Breath: Gasping for air, even while resting, or waking up suddenly at night struggling to breathe ^[3]^[4].
Fainting or Near-Fainting: Any loss of consciousness (syncope) or sudden, profound lightheadedness ^[5].
Signs of a Stroke: Sudden weakness on one side of the body, facial drooping, or slurred speech ^[6].
Major Bleeding: Coughing up blood, vomiting material that looks like coffee grounds, or passing stools that are black and tarry. Do not wait for a doctor’s callback for these ^[7]^[8].
Signs of Shock: Feeling suddenly cold, clammy, pale, or extremely confused ^[9].

Same-Day or Urgent Warning Signs

These symptoms are not always emergencies, but they suggest your heart is struggling, your medications need adjustment, or you need urgent evaluation. Call your cardiology team the same day (or seek emergency care depending on severity) if you notice:

Rapid Weight Gain: A gain of 2–3 pounds in a single day or 5 pounds in a week. This is often a sign of fluid buildup from heart failure ^[10].
New Swelling: Increased puffiness in your ankles, feet, or abdomen ^[10].
Increasing Fatigue: Feeling significantly more tired or short of breath during activities that were easy a few days ago ^[11].
Severe Dizziness or Medication Side Effects: Severe or fall-producing postural dizziness requires same-day or emergency assessment. A heart rate that feels consistently too slow or too fast also requires evaluation ^[12]^[7].
Bleeding that Will Not Stop: A nosebleed or other bleeding that will not stop requires urgent evaluation. While mild bruising may be expected with antiplatelet therapy, report it if it is extensive, rapidly increasing, or accompanied by other bleeding ^[7].

The Healing Timeline: Monitoring Progress

Your heart does not finish healing the day you leave the hospital. Long-term monitoring ensures that your pumping power (LVEF) is recovering and that your medications are working.

The Reassessment: If your heart’s pumping power was low (e.g., LVEF ≤40%) during your heart attack, you will likely have a repeat echocardiogram roughly >40 days to 3 months later after optimization of therapy ^[13]^[14]. This allows time for “reverse remodeling”—the process where the heart muscle strengthens and shrinks back toward a normal size ^[15].
Heart Failure Labs: If heart failure is suspected or being managed, you may need blood tests to check your kidney function, potassium levels, and natriuretic peptides (BNP or NT-proBNP), which are markers of heart stress ^[16]^[17].

Understanding the ICD Decision

If your heart’s pumping power remains significantly low (LVEF ≤35%) despite optimized guideline-directed therapy and appropriate recovery time, your doctor may discuss a referral for an Implantable Cardioverter Defibrillator (ICD) ^[15]^[14].

The Purpose: An ICD is a small device that monitors your heart rhythm 24/7. If it detects a life-threatening, “electrical” heart rhythm, it can deliver a life-saving shock ^[18].
Primary Prevention Timing: For primary prevention, guidelines generally require waiting at least 40 days after a heart attack and approximately 90 days after revascularization (like PCI or bypass surgery) before implanting an ICD ^[15]^[19]. This is because many patients see their heart function improve significantly once their medications are optimized ^[20].
Secondary Prevention: Patients with sustained ventricular arrhythmia or cardiac arrest may qualify under different, earlier secondary-prevention criteria.
Wearable Options: During the waiting period, a wearable cardioverter-defibrillator is an individualized, evidence-limited bridge that might be discussed, but it is not routine ^[21].

Symptom	Action Level	Possible Cause
New or unexplained chest pain/pressure	Emergency (911)	Recurrent MI or stent clot
Black, tarry stools	Emergency (911)	Major internal bleeding
Sudden weight gain	Same-Day Call	Fluid overload/Heart failure
Severe postural dizziness	Same-Day / Urgent	Low blood pressure from meds
Mild bruising	Monitor at Home	Normal effect of blood thinners

(References for Table: ^[1]^[7]^[10])

Common questions in this guide

Which symptoms after a heart attack mean I should call 911?

Call 911 for new or recurrent chest pressure or pain, severe trouble breathing at rest, fainting, stroke signs such as one-sided weakness or slurred speech, major bleeding, or sudden cold, clammy skin or extreme confusion. Do not drive yourself to the hospital because these symptoms can signal a life-threatening complication.

How much weight gain after a heart attack is concerning?

A gain of 2 to 3 pounds in one day or 5 pounds in a week can signal fluid buildup, especially if it occurs with swelling or increasing breathlessness. Contact your cardiology team the same day for guidance.

When do I need another echocardiogram after a heart attack?

If your heart’s pumping strength was low, such as an LVEF of 40% or less, your clinician may repeat an echocardiogram more than 40 days to about 3 months after the heart attack, after treatment has been optimized. The exact date depends on your recovery and care plan.

When might an ICD be considered after a heart attack?

If heart pumping strength remains 35% or lower despite optimized treatment and enough recovery time, your doctor may discuss an implantable cardioverter-defibrillator, or ICD. For primary prevention, implantation is generally delayed at least 40 days after a heart attack and about 90 days after a stent procedure or bypass surgery; earlier criteria may apply after cardiac arrest or sustained dangerous ventricular rhythms.

What bleeding or bruising should I report after a heart attack?

Call 911 for coughing up blood, vomiting material that looks like coffee grounds, or black, tarry stools. Bleeding that will not stop needs urgent evaluation, while mild bruising can occur with antiplatelet medicines but should be reported if it is extensive, rapidly increasing, or accompanied by other bleeding.

Could dizziness or a fast or slow heart rate be a medication problem after a heart attack?

Severe or fall-producing dizziness when standing, or a heart rate that stays unusually slow or fast, needs same-day or emergency assessment. These symptoms can reflect low blood pressure from medicines, a heart-rhythm problem, or another complication, so do not wait for the next routine visit.

Curated prompts to bring to your next appointment.

1.What was my LVEF at discharge, and on what date is my follow-up echocardiogram scheduled?
2.Given my current heart function, do I meet the criteria for a wearable cardioverter-defibrillator (WCD) while we wait for my heart to heal?
3.If I start experiencing a dry cough or lightheadedness on my new heart failure medications, should I call the office or wait for my next visit?
4.At what point would we consider a referral to an electrophysiologist to discuss an ICD?
5.If I notice blood in my urine or black stools, which of my doctors should I call first?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

Call 911 rather than driving for recurrent or unexplained chest discomfort, severe shortness of breath, fainting, stroke signs, shock, or major bleeding after a heart attack.
Same-day evaluation is warranted for rapid weight gain, new swelling, worsening fatigue or breathlessness, severe dizziness, an unusually fast or slow heart rate, or bleeding that will not stop.
People with an LVEF of 40% or less may need a repeat echocardiogram more than 40 days to about 3 months after a heart attack after treatment is optimized.
If LVEF remains 35% or lower despite optimized treatment and recovery time, clinicians may discuss an implantable cardioverter-defibrillator; timing differs for primary and secondary prevention.
Daily weights and tracking symptoms or medication effects help the patient and cardiology team detect fluid buildup or treatment problems.

References (21)

1
Rehospitalizations Following Primary Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction: Results From a Multi-Center Randomized Trial.
Spitzer E, Frei M, Zaugg S, et al.
Journal of the American Heart Association 2017; (6(8)) doi:10.1161/JAHA.117.005926.
PMID: 28780509
2
Cardiac arrests in general practice clinics or witnessed by emergency medical services: a 20-year retrospective study.
Haskins B, Nehme Z, Cameron PA, Smith K
The Medical journal of Australia 2021; (215(5)):222-227 doi:10.5694/mja2.51139.
PMID: 34121187
3
High-Sensitivity Troponin I Assay for Differential Diagnosis of New-Onset Myocardial Infarction in Patients with Acute Decompensated Heart Failure.
Han JH, Hwang SO, Cha KC, et al.
Yonsei medical journal 2021; (62(2)):129-136 doi:10.3349/ymj.2021.62.2.129.
PMID: 33527792
4
Platelet to Lymphocyte Ratio on Admission and Prognosis in Patients with Acute Cardiogenic Pulmonary Edema.
Demir M, Duyuler PT, Guray U, Celik MC
The Journal of emergency medicine 2018; (55(4)):465-471 doi:10.1016/j.jemermed.2018.06.021.
PMID: 30115388
5
Stress-Induced Cardiomyopathy Raising Concern for Myocardial Ischemia.
Singh A, Everest S, Nguyen L, et al.
Cureus 2022; (14(2)):e22091 doi:10.7759/cureus.22091.
PMID: 35308754
6
Vertebral Artery Dissection and Takotsubo Syndrome Associated with Marijuana Use.
Sanchez-Nadales A, Anampa-Guzmán A
Cureus 2019; (11(5)):e4785 doi:10.7759/cureus.4785.
PMID: 31367503
7
Hematuria Management in Patients on Antiplatelet Medications After Acute Coronary Syndrome: A Review of the Current Evidence and Recommendations.
Loufopoulos I, Kapriniotis K, Fyntanidou B, et al.
Reviews in cardiovascular medicine 2026; (27(3)):46334 doi:10.31083/RCM46334.
PMID: 41923731
8
[Severe bleeding with antiplatelet therapy: What to do?]
Cayla G, Cornillet L, Ledermann B, et al.
Presse medicale (Paris, France : 1983) 2019; (48(12)):1416-1421 doi:10.1016/j.lpm.2019.08.017.
PMID: 31679898
9
Clinical picture and risk prediction of short-term mortality in cardiogenic shock.
Harjola VP, Lassus J, Sionis A, et al.
European journal of heart failure 2015; (17(5)):501-9 doi:10.1002/ejhf.260.
PMID: 25820680
10
Effects of bisoprolol combined with torasemide on cardiac electrophysiology in patients with acute myocardial infarction and heart failure.
Jing L, Shi Q, Zhao S
Frontiers in physiology 2025; (16()):1629758 doi:10.3389/fphys.2025.1629758.
PMID: 40843126
11
15-Year trends, predictors, and outcomes of heart failure hospitalization complicating first acute myocardial infarction in the modern percutaneous coronary intervention era.
Rashid M, Abramov D, Naseer MU, et al.
European heart journal open 2025; (5(2)):oeaf013 doi:10.1093/ehjopen/oeaf013.
PMID: 40078653
12
Routine beta-blocker therapy after acute coronary syndromes: The end of an era?
Johner N, Gencer B, Roffi M
European journal of clinical investigation 2024; (54(12)):e14309 doi:10.1111/eci.14309.
PMID: 39257189
13
Predictors of Left Ventricular Ejection Fraction Decrease in Patients With ST-Segment Elevation Myocardial Infarction.
Pereverzeva KG, Yakushin SS, Tishkina IE, et al.
Kardiologiia 2024; (64(12)):27-34 doi:10.18087/cardio.2024.12.n2729.
PMID: 39784130
14
The Optimal Timing of Primary Prevention Implantable Cardioverter-Defibrillator Referral in the Rapidly Changing Medical Landscape.
Wong JA, Roberts JD, Healey JS
The Canadian journal of cardiology 2021; (37(4)):644-654 doi:10.1016/j.cjca.2021.01.024.
PMID: 33549824
15
Prediction of early death after myocardial infarction in patients with reduced left ventricular ejection fraction. The search for new indications for cardioverter-defibrillator implantation (ICD).
Pres D, Tajstra M, Mitkowski P, et al.
Kardiologia polska 2021; (79(12)):1343-1352 doi:10.33963/KP.a2021.0177.
PMID: 34897630
16
Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction.
Liu LW, Wu PC, Chiu MY, et al.
Acta Cardiologica Sinica 2020; (36(2)):125-132 doi:10.6515/ACS.202003_36(2).20190812A.
PMID: 32201463
17
Effects of dapagliflozin on heart rate variability, cardiac function, and short-term prognosis in early-onset post-myocardial infarction heart failure.
Zhou L, Niu M, Chen W, et al.
Frontiers in cardiovascular medicine 2024; (11()):1490316 doi:10.3389/fcvm.2024.1490316.
PMID: 39834729
18
Added Value of 3- Versus 2-Dimensional Echocardiography Left Ventricular Ejection Fraction to Predict Arrhythmic Risk in Patients With Left Ventricular Dysfunction.
Rodríguez-Zanella H, Muraru D, Secco E, et al.
JACC. Cardiovascular imaging 2019; (12(10)):1917-1926 doi:10.1016/j.jcmg.2018.07.011.
PMID: 30219408
19
Sudden Cardiac Death in Ischaemic Cardiomyopathy and the Primary Prevention ICD: Time for a More a Personalised Approach?
Ezad SM, Babu G, O'Kane P
Interventional cardiology (London, England) 2023; (18()):e11 doi:10.15420/icr.2022.14.
PMID: 37398871
20
Role of Implantable Cardioverter Defibrillator in Heart Failure With Contemporary Medical Therapy.
Butler J, Talha KM, Aktas MK, et al.
Circulation. Heart failure 2022; (15(8)):e009634 doi:10.1161/CIRCHEARTFAILURE.122.009634.
PMID: 35726617
21
Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
Duncker D, König T, Hohmann S, et al.
Journal of the American Heart Association 2017; (6(1)) doi:10.1161/JAHA.116.004512.
PMID: 28096098

This page explains warning signs and follow-up after a myocardial infarction for educational purposes only and does not replace medical advice. Call 911 for emergency symptoms and ask your cardiology team how these recommendations apply to you.

Get notified when new evidence is published on myocardial infarction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents